

Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus

September 6 2012

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

This discovery by the team of scientists led by Professor Antonio Bertoletti, programme director and research director of the infection and immunity programme at SICS, could lead to a [paradigm shift](#) in the current treatment of patients with chronic HBV. The findings were published in *Gastroenterology* on 1st September.

Current guidelines from international liver associations recommend delaying therapy until HBV carriers show clear signs of active liver disease, which generally appear after the age of 30 . This is based on two assumptions. One, young patients are unable to react to treatment because they are immune-tolerant to the virus. This means that there is no protective immune response in their body to help them get rid of the virus, and therefore, they will not run the risk of [liver damage](#) or inflammation. Two, HBV infection is largely harmless in HBV carriers until active [liver disease](#) is apparent.

However, Professor Bertoletti and his team showed that young patients

are not immune tolerant as they possess HBV-specific [T cells](#) with the ability to produce distinct antiviral cytokines that help the body fight against HBV. They also showed that the longer a patient is left untreated, the less effective their immune system becomes against HBV and the less able the patient will be able to clear the virus from their body even when they receive treatment.

The scientists demonstrated that the presence of HBV in the body over a long period of time is harmful to the patient due to repeated activation of T-cells which induces a progressive state of T-cell exhaustion, a state of immune system dysfunction that prevents optimal control of the infection and clearance of the virus from the body. Thus, young patients produce an [immune response](#) against HBV which is less compromised than that in older patients.

Professor Bertoletti said, "Young patients infected with HBV are most at risk of developing chronic HBV but current guidelines mean that they are also the least likely to be treated. However, our findings suggest that it might be better to start treatment early as young people with their stronger [immune system](#), respond better to treatment and are more able to clear the virus."

Prof Judith Swain, Executive Director of SICS, said, "These findings may change the way treatment is applied to patients with HBV in hospitals in Singapore and throughout the world. This is a fine example of how clinicians, physician scientists, and scientists work together to improve healthcare for the public."

More information: The paper can be accessed at [www.gastrojournal.org/article/ ... \(12\)00840-2/abstract](http://www.gastrojournal.org/article/... (12)00840-2/abstract)

Provided by Agency for Science, Technology and Research (A*STAR),
Singapore

Citation: Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus (2012, September 6) retrieved 25 April 2024 from
<https://medicalxpress.com/news/2012-09-earlier-treatment-young-patients-chronic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.